Hormonal
Androgen deprivation therapy (ADT) for prostate cancer causes significant metabolic complications, including insulin resistance, hyperglycemia, and metabolic syndrome, which accelerate cardiovascular mortality.
If you are undergoing Androgen Deprivation Therapy for prostate cancer, you are at a significantly higher risk for developing diabetes, high cholesterol, and heart disease. You must undergo regular screening for blood sugar and lipids. Aggressively manage your weight, diet, and exercise to counteract the muscle loss and fat gain caused by the therapy. Discuss cardiovascular risk with your doctor before starting treatment.
Metabolic complications such as insulin resistance, diabetes, and metabolic syndrome have recently surfaced and may be responsible for the increased cardiovascular mortality seen in these men.
Why this rating
Based on multiple prospective and cross-sectional studies, though the authors note a need for long-term prospective data to establish causality definitively.
Source
Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis
Sadeka Shahani et al. · The Journal of Clinical Endocrinology & Metabolism · 2008
DOI 10.1210/jc.2007-2595
More from this paper
- Short-term ADT (3-6 months) induces insulin resistance and hyperinsulinemia while maintaining normal fasting glucose levels, whereas long-term ADT (12+ months) leads to frank hyperglycemia and diabetes.Good
- ADT causes unfavorable body composition changes, specifically increasing fat mass (particularly visceral/subcutaneous) and decreasing lean body mass, which correlates with rising insulin levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →